CN109893541B - 经血干细胞来源的外泌体在制备治疗***的药物中的应用 - Google Patents
经血干细胞来源的外泌体在制备治疗***的药物中的应用 Download PDFInfo
- Publication number
- CN109893541B CN109893541B CN201910295273.6A CN201910295273A CN109893541B CN 109893541 B CN109893541 B CN 109893541B CN 201910295273 A CN201910295273 A CN 201910295273A CN 109893541 B CN109893541 B CN 109893541B
- Authority
- CN
- China
- Prior art keywords
- exosome
- stem cells
- cells
- cell
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 63
- 210000004369 blood Anatomy 0.000 title claims abstract description 62
- 239000008280 blood Substances 0.000 title claims abstract description 62
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 54
- 230000002175 menstrual effect Effects 0.000 title claims abstract description 35
- 208000028685 Asherman syndrome Diseases 0.000 title claims abstract description 31
- 201000001389 adhesions of uterus Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 239000006228 supernatant Substances 0.000 claims abstract description 13
- 238000012258 culturing Methods 0.000 claims abstract description 11
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 8
- 238000000926 separation method Methods 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 3
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 239000006285 cell suspension Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 6
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 102100025222 CD63 antigen Human genes 0.000 claims description 4
- 102100027221 CD81 antigen Human genes 0.000 claims description 4
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 claims description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 claims description 4
- 238000007664 blowing Methods 0.000 claims description 4
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 102100032912 CD44 antigen Human genes 0.000 claims description 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 238000010009 beating Methods 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims description 3
- 230000005906 menstruation Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000001262 western blot Methods 0.000 claims description 3
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 102100037241 Endoglin Human genes 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 241000606153 Chlamydia trachomatis Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 241000204051 Mycoplasma genitalium Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229940038705 chlamydia trachomatis Drugs 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 208000006379 syphilis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 230000008827 biological function Effects 0.000 abstract description 3
- 238000005138 cryopreservation Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 238000002689 xenotransplantation Methods 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 2
- 230000003278 mimic effect Effects 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 238000005199 ultracentrifugation Methods 0.000 abstract description 2
- 230000002357 endometrial effect Effects 0.000 description 22
- 210000004696 endometrium Anatomy 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 241000700159 Rattus Species 0.000 description 11
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000010410 layer Substances 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 210000004907 gland Anatomy 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 238000011476 stem cell transplantation Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 102100031168 CCN family member 2 Human genes 0.000 description 1
- 101150091877 Ccn2 gene Proteins 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000002777 Gynatresia Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000648544 Homo sapiens Sushi domain-containing protein 2 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102100028854 Sushi domain-containing protein 2 Human genes 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000008339 endometrial blood flow Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002346 layers by function Substances 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 238000011133 mesenchymal stem cell therapy Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910295273.6A CN109893541B (zh) | 2019-04-12 | 2019-04-12 | 经血干细胞来源的外泌体在制备治疗***的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910295273.6A CN109893541B (zh) | 2019-04-12 | 2019-04-12 | 经血干细胞来源的外泌体在制备治疗***的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109893541A CN109893541A (zh) | 2019-06-18 |
CN109893541B true CN109893541B (zh) | 2021-11-02 |
Family
ID=66954799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910295273.6A Active CN109893541B (zh) | 2019-04-12 | 2019-04-12 | 经血干细胞来源的外泌体在制备治疗***的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109893541B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111979199B (zh) * | 2020-07-09 | 2023-08-01 | 浙江普慧医疗科技有限公司 | 用于治疗***的宫血干细胞和外泌体 |
CN112704721A (zh) * | 2020-12-02 | 2021-04-27 | 焕生汇生物基因技术(北京)有限公司 | 一种宫内膜干细胞外泌体凝胶 |
CN115404205A (zh) * | 2022-03-01 | 2022-11-29 | 浙江生创精准医疗科技有限公司 | 一种新型外泌体及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106309491A (zh) * | 2016-08-22 | 2017-01-11 | 中国医科大学附属盛京医院 | 经血干细胞在制备治疗***的药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170119682A1 (en) * | 2015-11-02 | 2017-05-04 | Tigenix, S.A.U. | Mesenchymal stem cell-derived exosomes and their uses |
-
2019
- 2019-04-12 CN CN201910295273.6A patent/CN109893541B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106309491A (zh) * | 2016-08-22 | 2017-01-11 | 中国医科大学附属盛京医院 | 经血干细胞在制备治疗***的药物中的应用 |
Non-Patent Citations (1)
Title |
---|
MSCs 来源的 exosome 修复受损子宫内膜的体内实验研究;王雪;《中国优秀硕士学位论文全文数据库,医药卫生科技辑,D046-61》;20181231;前言、3.4节、第1.2.1.1、1.2.1.2、1.2.2.1节 * |
Also Published As
Publication number | Publication date |
---|---|
CN109893541A (zh) | 2019-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200188446A1 (en) | Renovation and Repopulation of Decellularized Tissues and Cadaveric Organs by Stem Cells | |
CN105861430B (zh) | 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用 | |
US11821005B2 (en) | Umbilical cord mesenchymal stem cells (MSCs) and culture method and application thereof | |
US20050014255A1 (en) | Stem cells for clinical and commercial uses | |
CN109893541B (zh) | 经血干细胞来源的外泌体在制备治疗***的药物中的应用 | |
CN102643784B (zh) | 一种造血干/祖细胞的体外扩增体系 | |
US9173903B2 (en) | Fluid associated with adult stem cells for medical, cosmetic, and veterinary use | |
US9211306B2 (en) | Cellular therapeutic agent for incontinence or urine comprising stem cells originated from decidua or adipose | |
CN106492194A (zh) | 一种干细胞外泌体制剂及其制备方法和应用 | |
CN106566803A (zh) | 一种培养液及其应用和培养脐带间充质干细胞的方法 | |
CN108865986A (zh) | 用于修复关节软骨损伤/缺损的间充质干细胞制剂及其制备方法和应用 | |
JP2024028920A (ja) | hMPCの集団をゼノフリー生成するための方法 | |
JP5388297B2 (ja) | アディポクラスター | |
CN109692184A (zh) | 一种经血干细胞制剂及其制备方法和应用 | |
CN114209814B (zh) | Tnfsf15蛋白在促进骨髓干细胞分化为巨噬细胞并扩增中的用途 | |
CN114874981A (zh) | 一种间充质干细胞外泌体及用于免疫细胞培养的用途 | |
CN108066750A (zh) | 干细胞及其分泌物用于治疗皮肤烧烫伤的新用途 | |
CN115786247B (zh) | 一种无血清培养基及其在维持毛囊活性、毛发养护及移植方面的应用 | |
BR112020004517A2 (pt) | células tronco derivadas de porco neonato e processo para sua preparação | |
CN103146646A (zh) | 一种动员间充质干细胞的制剂及分离方法 | |
WO2012115298A1 (ko) | 양수 유래 줄기세포를 함유하는 요실금 치료제 | |
KR20130102506A (ko) | 성숙 낭성 기형종 유래 세포 및 조직의 용도 | |
KR101289834B1 (ko) | 양수 유래 줄기세포를 함유하는 요실금 치료제 | |
KR101423659B1 (ko) | 초기 분화된 양수 줄기세포를 포함하는 요실금 치료제 | |
Li et al. | The Efficacy and Mechanism of Autologous Fat Stem Cells Combined with Microcarrier 6 Transplantation for Anal Fistula Treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240419 Address after: Room 101, Building B7, Life Science Industrial Park, 140 Jinye Avenue, Sanxi Community, Kuiyong Street, Dapeng New District, Shenzhen, Guangdong Province, 518120 Patentee after: Shenzhen City, Huan Hao Technology Co.,Ltd. Country or region after: China Address before: 110003, 36, Miyoshi street, Heping District, Liaoning, Shenyang Patentee before: SHENGJING HOSPITAL OF CHINA MEDICAL University Country or region before: China |